Yahoo Finance

Acid Sphingomyelinase Deficiency (ASMD) Market Analysis and Forecast, 2025-2035 - Xenpozyme Gains Global Market Approval, Boosting Diagnosis and Treatment Rates

Dublin, Nov. 21, 2025 (GLOBE NEWSWIRE) -- The "Acid Sphingomyelinase Deficiency Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's ...
Nasdaq

Sanofi : Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency

Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency “These significant results for olipudase ...
Business Wire

PicnicHealth and Wylder Nation Foundation Announce ASMD Accelerate to Contribute to Acid Sphingomyelinase Deficiency Research

SAN FRANCISCO & SCOTTSDALE, Ariz.--(BUSINESS WIRE)--PicnicHealth, the venture-backed startup giving patients unprecedented access to their medical records and the ability to contribute to scientific ...
Monthly Prescribing Reference

Xenpozyme Approved for Acid Sphingomyelinase Deficiency

Xenpozyme is a hydrolytic lysosomal sphingomyelin-specific enzyme replacement therapy designed to replace deficient or defective ASM. The Food and Drug Administration (FDA) has approved Xenpozyme ™ ...
The American Journal of Managed Care

Review Identifies Elevated Cancer Prevalence in Patients With ASMD

A small cohort of patients with acid sphingomyelinase deficiency (ASMD) showed higher rates of cancer compared with the general population, according to recent findings. Acid sphingomyelinase ...
Nasdaq

Sanofi: Trials Show Positive Topline Results In Acid Sphingomyelinase Deficiency

(RTTNews) - Sanofi (SNYNF, SNY) said, Olipudase alfa showed positive results in two clinical trials in the treatment of acid sphingomyelinase deficiency in adult and pediatric patients. The randomized ...
The American Journal of Managed Care

Case Study Suggests Further Research on Benign Focal Hepatic Lesions in ASMD

Imaging studies and subsequent biopsies of a liver lesion showed a foamy macrophages aggregate in a 30-year-old patient with acid sphingomyelinase deficiency (ASMD) similar to those found in Gaucher ...
Medical Xpress

FDA approves first treatment for acid sphingomyelinase deficiency

The U.S. Food and Drug Administration has approved Xenpozyme (olipudase alfa) for pediatric and adult patients with acid sphingomyelinase deficiency (ASMD), a rare genetic disease. ASMD is caused by ...
Monthly Prescribing Reference

Olipudase Alfa Improves Lung Function, Spleen Volume in ASMD

ASMD is a rare, debilitating lysosomal storage disease characterized by a deficiency of the enzyme acid sphingomyelinase, which results in the accumulation of sphingomyelin in various tissues of the ...
Healio

First treatment for acid sphingomyelinase deficiency approved in Japan

Please provide your email address to receive an email when new articles are posted on . The Japan Ministry of Health, Labor and Welfare has authorized Xenpozyme for the treatment of adult and ...
Healio

FDA approves Xenpozyme, first treatment for rare acid sphingomyelinase deficiency

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Xenpozyme as the first treatment for patients with acid sphingomyelinase deficiency with ...